A quinazoline diuretic, with properties generally similar to the thiazide diuretics.
Interferes with the renal tubular mechanism of electrolyte reabsorption.
Trade name Zaroxolyn.
Acts primarily to inhibit sodium reabsorption at the cortical diluting site and to a lesser extent in the proximal convoluted tubule.
Sodium and chloride ions are excreted in approximately equivalent amounts.
The increased delivery of sodium to the distal tubular exchange site causes increased potassium excretion.
Results in increased excretion of phosphate and magnesium ions.
Increases excretion of sodium in patients with severely compromised glomerular filtration.
Diuresis and saluresis usually begin within one hour of oral administration and may persist for 24 hours or more.
Single daily dose is recommended.
Unlike thiazides, it may produce diuresis in patients with glomerular filtration rates below 20 mL/min.
When administered concurrently with furosemide may have marked diuresis.
Maximum blood levels are found approximately eight hours after dosing.
Most of the drug is excreted in the urine unchanged.
Indications for the treatment of salt and water retention including congestive heart failure, nephrotic syndrome, hypertension,and renal disease associated edema.